Get the Stockscreener App
1.30
5.80%
-0.08
After Hours:
1.30
Pacific Biosciences Of California Inc stock is traded at $1.30, with a volume of 9.67M.
It is down -5.80% in the last 24 hours and up +25.60% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.38
Open:
$1.36
24h Volume:
9.67M
Relative Volume:
1.13
Market Cap:
$360.10M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-0.8667
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+12.07%
1M Performance:
+25.60%
6M Performance:
-34.01%
1Y Performance:
-22.16%
1-Day Range:
$1.28
$1.38
1-Week Range:
$1.12
$1.40
52-Week Range:
$0.8511
$2.72
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.30 | 360.10M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
132.28 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
SYK
Stryker Corp
|
373.37 | 147.15B | 23.22B | 2.86B | 3.58B | 7.40 |
|
BSX
Boston Scientific Corp
|
101.73 | 146.97B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
86.17 | 112.11B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
73.27 | 44.79B | 5.54B | 4.18B | 623.10M | 7.00 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Here's Why You Should Add PacBio Stock to Your Portfolio Now - MSN
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Following a 41% decline over last year, recent gains may please Pacific Biosciences of California, Inc. (NASDAQ:PACB) institutional owners - simplywall.st
Celebrating Father’s Day with new discoveries of the Y chromosome achieved with HiFi sequencing - PacBio
Transcript : Pacific Biosciences of California, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - marketscreener.com
PACB Q1 Earnings Call: Cost Reductions and Clinical Adoption Offset Market Headwinds - Yahoo Finance
Pacific Biosciences Approves Key Proposals at Annual Meeting - TipRanks
Powered by PacBio: Selected publications from May 2025 - PacBio
Pacific Biosciences Of California To Present At Jefferies Conference; Webcast At 8:45 AM ET - Nasdaq
Amgen To Present At Jefferies Healthcare Conference; Webcast At 9:20 AM ET - Nasdaq
Q1 Earnings Roundup: PacBio (NASDAQ:PACB) And The Rest Of The Life Sciences Tools & Services Segment - Yahoo Finance
Pacific Biosciences of California, Target ALS Collaborate for Genomic Study - marketscreener.com
PacBio (PACB) Joins Forces with Target ALS for Major Genomic Study | PACB Stock News - GuruFocus
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date - marketscreener.com
Pacific Biosciences of California: Sell Before Potential Reverse Split - Seeking Alpha
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacific Biosciences of California, Inc. (PACB) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Media resourceS - PacBio
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy - sharewise
PureTarget repeat expansion and carrier panels enable high-throughput clinical research solutions - PacBio
PacBio to Present at Upcoming Investor Conferences - Yahoo Finance
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q1 2025 Earnings Call Transcript - MSN
PacBio Stock Slips Despite New China Distribution Deal With Haorui - sharewise
PACB stock touches 52-week low at $0.94 amid market challenges - Investing.com Australia
PacBio (PACB) Expands Presence in China with New Distribution De - GuruFocus
PacBio (PACB) Expands Presence in China with New Distribution Deal | PACB Stock News - GuruFocus
PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene - Yahoo Finance
HiFi sequencing uncovers the secret to aging gracefully in Earth’s oldest living organisms - PacBio
Pacific Biosciences: A Mountain Of Red Flags (NASDAQ:PACB) - Seeking Alpha
Potential Upside For Pacific Biosciences of California, Inc. (NASDAQ:PACB) Not Without Risk - simplywall.st
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences - GuruFocus
PACB: Piper Sandler Adjusts Price Target for Pacific Biosciences | PACB Stock News - GuruFocus
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock N - GuruFocus
Where Pacific Biosciences Stands With Analysts - Benzinga
PACB: Stephens & Co. Reiterates Overweight Rating | PACB Stock News - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly R - GuruFocus
PACB Price Target Reduced by Piper Sandler Following Quarterly Results | PACB Stock News - GuruFocus
PacBio clears allegations after special investigation By Investing.com - Investing.com Nigeria
Metagenomics Market Size, Share, Forecast & Trends Analysis Report 2025: Market to Soar to $6.71 Billion by 2031, Driven by Agri Genomics and Genome Mapping - GlobeNewswire Inc.
PACB Stock May Rise Following the Deal With Chulalongkorn University - Nasdaq
PacBio (PACB) Completes Probe into Employment Practices and Cybe - GuruFocus
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated - Yahoo Finance
Pacbio adjusts 2025 revenue guidance to $150M-$170M amid macroeconomic challenges - MSN
Pacific Biosciences of California First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
PacBio (PACB) Sees Increased Options Activity Ahead of Earnings - GuruFocus
PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates - Yahoo Finance
Pacific Biosciences of California Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pacific Biosciences Of California Inc Stock (PACB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HENRY CHRISTIAN O | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
12,497 |
17,583 |
2,225,357 |
| Van Oene Mark | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
6,486 |
9,126 |
1,497,695 |
| Farmer Michele | See Remarks |
Mar 03 '25 |
Sale |
1.41 |
2,973 |
4,183 |
184,619 |
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):